GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 180 Life Sciences Corp (NAS:ATNF) » Definitions » Valuation Rank

ATNF (180 Life Sciences) Valuation Rank


View and export this data going back to 2017. Start your Free Trial

What is 180 Life Sciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

180 Life Sciences Valuation Rank Related Terms

Thank you for viewing the detailed overview of 180 Life Sciences's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

180 Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 180 Life Sciences Corp (NAS:ATNF) » Definitions » Valuation Rank
Comparable Companies
OGEN SNPX LIPO PKTX CDT ARTL ALLR GRI AAGH THAR VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA, USA, 94306
Website
https://www.180lifesciences.com
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
Executives
James N. Woody director, officer: Chief Executive Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Marc Feldmann director 5 DURHAM TERRACE, LONDON X0 W25PB
Lawrence Steinman director 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Mcgovern Jr. Donald A. director C/O CARS.COM, 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Quan Anh Vu officer: COO / Chief Business Officer 22616 ERWIN STREET, WOODLAND HILLS CA 91367
Ozan Pamir officer: Interim CFO 2443 FILLMORE ST #380-17649, SAN FRANCISCO CA 94115
Pamela G Marrone director C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618
Teresa Deluca director 40 BURTON HILLS BOULEVARD, SUITE 500, NASHVILLE TN 37215
Russell T Ray director 2525 DUPONT DR, IRVINE CA 92612
Knuettel Ii Francis director 205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
Marlene Krauss director, 10 percent owner, officer: Chief Executive Officer C/O KBL HEALTHCARE INC, 645 MADISON AVE, NEW YORK NY 10022
Lawrence Marshall Gold director 830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025
Jonathan B. Rothbard officer: Chief Scientific Officer 501 BEALE STREET, UNIT 8D, SAN FRANCISCO CA 94105
Shoshana Shendelman director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Richard W Barker director 290 COMMONWEALTH AVENUE #17, BOSTON MA 02115